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Abstract: Background: Little is known about the potential of statin-induced high-density lipoprotein cholesterol (HDL-C) 
increase to improve renal function in coronary heart disease (CHD) patients. 
Methods and Results: In this post hoc analysis of the GREek Atorvastatin and Coronary heart disease Evaluation 
(GREACE) Study we investigated the effect of HDL-C increase after statin treatment on renal function. From a total of 
1,600 patients, 880 were on various statins (mainly atorvastatin) and 720 were not. Other secondary prevention therapies 
were similar in the 2 groups. After a 3 year follow up, the lipid profile was unchanged in the statin untreated group and es-
timated glomerular filtration rate (eGFR) was reduced by 5.1% compared with baseline (P<0.0001). In contrast, in the 
statin treated group non-HDL-C was reduced by 43%, HDL-C was increased by 7% and there was a significant increase 
in eGFR compared with baseline by 9.8% (P<0.0001). In multiple regression analysis, the mean 7% increase in HDL-C in 
the treated arm during the entire study was associated with a 5.6% increase in eGFR recorded after the 6
th week of treat-
ment. The odds ratio of eGFR increase with every 5% statin-induced rise in HDL-C was 1.78 (95% confidence interval 
1.19-3.34; P=0.001). 
Conclusions: Statin treatment significantly improved renal function. Statin-induced HDL-C increase significantly and in-
dependently contributed to this improvement. This finding supports the concept that improving lipid variables other than 
low density lipoprotein cholesterol is also beneficial to preserving renal function. 
Keywords: Renal function, chronic kidney disease, dyslipidaemia, statins, high density lipoprotein, and coronary heart disease. 
INTRODUCTION 
  Chronic kidney disease (CKD), including mild renal im-
pairment, is recognized as an independent predictor of car-
diovascular disease (CVD) in high-risk patients [1-3]. Simi-
larly, in the general population there seems to be a graded 
association between a reduced glomerular filtration rate 
(GFR) and the risk of death, CVD events and hospitalization 
[4]. 
  Dyslipidaemia is an independent risk factor for both 
CVD and CKD. The Physicians’
 Health Study reported that 
from 4,483 participating healthy men with a normal baseline 
renal function, those with low high-density lipoprotein cho-
lesterol (HDL-C) and high non-HDL-C [low-density lipopro-
tein cholesterol (LDL-C) + very LDL-C (VLDL-C) + inter-
mediate density lipoprotein cholesterol (IDL-C)] levels had 
double the risk for CKD after adjusting for other risk factors 
[5]. A recent study also showed that high apolipoprotein B  
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and non-HDL-C levels were associated with an increased 
risk for deterioration of renal function in patients with CKD 
[6]. The issue is whether or not hypolipidaemic drug treat-
ment is able to reverse this process. 
  The results of the Helsinki Heart Study [7] and the Vet-
erans Affairs High-Density Lipoprotein Intervention Trial 
(VA-HIT) [8] showed that fibrates might not exert a clini-
cally relevant effect on rates of kidney function loss in indi-
viduals with low HDL-C and elevated non-HDL-C. The 
Heart Protection Study (HPS) showed that allocation to sim-
vastatin significantly attenuated the fall in estimated-GFR 
(eGFR) compared with placebo [9]. A pooled analysis of 3 
pravastatin survival trials also showed a decreased deteriora-
tion of renal function with pravastatin compared with pla-
cebo [10]. In the GREek Atorvastatin and Coronary heart 
disease Evaluation (GREACE) Study, statin treatment sig-
nificantly increased eGFR by 12% and reduced serum uric 
acid levels, whereas renal function deteriorated in usual care 
patients [11-13]. Of note, the GREACE trial [11-13] showed 
that statin-induced improvement of eGFR was more evident 
in patients with mild renal impairment and contributed to the 
reduction in CVD events (multivariate analysis). A post hoc 
analysis of the Treating to New Targets (TNT) trial showed 
that over the 5 year study period there was a significant by Statins, HDL-C, and Renal Function  The Open Cardiovascular Medicine Journal, 2007, Volume 1    9 
5.6% and 8.4% increase in eGFR with both doses of atorvas-
tatin (10 and 80 mg/day, respectively) instead of the ex-
pected decline of about 5 mL/min/1.73 m
2 [14]. 
  However, it is not yet clear whether the relatively small 
increases in HDL-C observed during statin therapy contrib-
ute to the improvement in renal function, beyond the estab-
lished beneficial effect of LDL-C reduction and non-HDL-C. 
In the present post hoc analysis of GREACE we address this 
issue. 
STUDY POPULATION - METHODS 
  Study design, patients and methods. The design of the 
GREACE study and its main findings have been previously 
described [11,12,15,16]. Briefly, GREACE included men 
(78%) and women (22%) with established coronary heart 
disease (CHD), aged <75 years (mean 58.3 years). Their 
serum LDL-C concentration was >100 mg/dL (2.6 mmol/L) 
and serum triglyceride (TG) levels <400 mg/dL (4.5 
mmol/L). All patients attended the Atherosclerosis or the 
Metabolic Syndrome Units of the Hippocration University 
Hospital, Thessaloniki, and if eligible were randomized ei-
ther into the structured care group, followed up by the Uni-
versity Clinic, or into the usual care group followed up by 
heart specialists or general practitioners of the patient’s 
choice outside the hospital. In the structured care group, the 
starting dose of atorvastatin was 10 mg/day. With evalua-
tions every 6 weeks the dose of atorvastatin was titrated up 
to 80 mg/day for patients not reaching the National Choles-
terol Education Program Adult Treatment Panel III (NCEP 
ATP III) LDL-C goal <100 mg/dL (2.6 mmol/L) with lower 
dosages. Patients in the usual care group were treated ac-
cording to their physician’s standard of care. Usual care con-
sisted of lifestyle changes plus necessary drug treatment, 
including lipid-lowering agents. Atorvastatin was not ex-
cluded from the usual care group. After dose titration pa-
tients were followed for a mean 3 year period with visits 
every 6 months. Serum creatinine (SCr) was measured using 
the Jaffé method (Olympus Diagnostica GmbH, Clare, Ire-
land); normal range 0.6-1.3 mg/dL (55-115 μmol/L). eGFR 
was calculated using the Modification of Diet in Renal Dis-
ease (MDRD) formula [17]. 
  The study subjects were randomized either to structured 
care (n=800) with dose titration of atorvastatin to achieve the 
LDL-C target of <100 mg/dl (2.6 mmol/L) or to usual care 
(n=800) that was followed by physicians of their choice. In 
this later group only 12% of subjects were on statin treat-
ment and only 3% were at LDL-C target. In the present post 
hoc analysis we divided participants into those on statin and 
those without statin treatment, irrespective to their initial 
allocation to structured or usual care groups. Patients with 
SCr levels above the reference range [>1.3 mg/dL (115 
μmol/L)] were excluded from the study. 
  Classification of CKD. In the Kidney Disease Outcomes 
and Quality Initiative (K/DOQI) guidelines [3], CKD is de-
fined according to the presence or absence of kidney damage 
and level of kidney function, irrespective of diagnosis. In 
this classification scheme including 5 stages, stage 1 is asso-
ciated with a normal eGFR (90 ml/min/1.73 m
2), stage 2 
with kidney damage and mildly decreased eGFR (60-89 
ml/min/1.73 m
2), stage 3 with moderately decreased eGFR 
(30-59 ml/min/1.73 m
2), stage 4 with severely decreased 
eGFR (15-29 ml/min/1.73 m
2) and stage 5 with an eGFR < 
15 ml/min/1.73 m
2. 
 Statistical  Analyses. Treatment-based analyses of all 
patients according to statin or no statin treatment were per-
formed. On study eGFR values were compared with those at 
baseline using ANOVA to assess differences over time 
within and between treatment groups. A univariate analysis 
was initially performed, including 25 predictors of renal 
function deterioration. Then, after removal of 6 predictors 
with a P > 0.10, 19 predictors were included in a multivariate 
Cox Predictive Model, involving backward stepwise logistic 
regression. All predictors were recorded as categorical fac-
tors (0-1). All univariate or multivariate analyses were per-
formed with an HDL-C by 4 mg/dl (0.1 mmol/L) stepwise 
increase or reduction from baseline. Data were expressed as 
mean values. Standard deviations are presented in both Ta-
bles 1 and 2. The SPSS 11.01 software package (SPSS, Inc., 
Chicago, IL) was used for all statistical analyses. A two-
tailed P < 0.05 was considered significant. 
RESULTS 
  Baseline characteristics of patients are shown in Table 1. 
1. Renal Function at Baseline 
  According to K/DOQI, 642 patients had a stage 1, 864 a 
stage 2, and 94 a stage 3 renal function status. Patients from 
each renal function status were similarly distributed in the 2 
analysed groups (Table 1). At baseline, eGFR in both ana-
lysed groups [with (n=880) or without (n=720) statin treat-
ment] was 72 mL/min/1.73 m
2 and 73 mL/min/1.73 m
2, re-
spectively (P = not significant). 
2. Effect of Dyslipidaemia and Statin Treatment on 
eGFR 
  A. No statin treatment (n=720). The 88% of the usual 
care group and those on atorvastatin that could not tolerate 
the drug formed this control group. There was a significant 
by 5.1% reduction in eGFR (P<0.0001 vs baseline) at the end 
of the 3 year period (Fig. 1). 
  B. Statin treatment (n=880). From patients allocated to 
a statin, 808 were on atorvastatin (mean dose 23 mg/day), 41 
were on simvastatin (mean dose 20 mg/day), 23 on pravas-
tatin (mean dose 24 mg/day) and 8 on fluvastatin (mean dose 
40 mg/day). These patients presented an increase in eGFR 
levels by 4.2% at the 6
th week of treatment (P<0.001 vs base-
line) and by 9.8% at the end of the study (P<0.0001 vs both 
baseline and 6
th week of treatment) (Fig. 1). The net increase 
in eGFR between 6
th week of treatment and the 3
rd year of 
treatment was 5.6% (Fig. 1). This increase was dependent on 
baseline eGFR levels. Patients with a eGFR < 77 
mL/min/1.73 m
2 (median value of all patients) had a mean 
increase in eGFR of 12.9% (P<0.0001), while patients with 
an eGFR > 77 mL/min/1.73 m
2 had a mean increase in eGFR 
of 4.5% (P=0.002). Thus, the greatest benefit from statin 
treatment was observed in those with early renal dysfunc-
tion. 
3. Lipid Profile at Baseline 
  Patients from both treatment groups had high total cho-
lesterol, LDL-C, non-HDL-C and TG levels (Table 2). HDL-
C was 39-40 mg/dl (1.0 mmol/l). Thus, the dyslipidaemia of 10    The Open Cardiovascular Medicine Journal, 2007, Volume 1  Athyros et al. 
the GREACE study could be characterized mostly as com-
bined hyperlipidaemia. 
4. Effect of Statin Treatment on the Lipid Profile 
  The lipid profile in the untreated group remained essen-
tially unchanged throughout the study (Table 2). In the statin 
treated group, 97% of patients (n=854) had mean LDL-C 
levels < 100 mg/dL (2.6 mmol/L) after the titration period 
(mean change -46%) and 98% of patients (n=898) had mean 
non-HDL-C levels < 130 mg/dL (3.4 mmol/L) after the titra-
tion period (mean change -43%). The mean increase in 
HDL-C was 7% (P<0.001 vs baseline and P=0.002 vs on-
study values in the usual care group). The LDL-C/HDL-C 
ratio was reduced by 49% (P<0.0001 vs both baseline and  
 
usual care), while the mean reduction in TGs was 30% 
(P<0.0001 vs baseline). 
5. Effect of HDL-C Increase on eGFR 
  Multiple regression analysis showed that the renal func-
tion improvement (estimated by eGFR increase) in patients 
receiving statins was associated with a reduction in athero-
genic lipoprotein levels as well as with the statin-induced 
increases in HDL-C (7% from baseline), over and above 
secondary CVD prevention therapies. This effect of HDL-C 
was seen in patients who achieved LDL-C levels <100 mg/dl 
(2.6 mmol/L) and non-HDL-C levels <130 mg/dl (3.36 
mmol/L). 
 
Table 1.  Baseline Characteristics of the Statin Treated and Untreated Groups 
 
Parameter  Statin Treated (N=880)  Statin Untreated (N=7200)  P Value 
Men/women (%)  79/21  78/22  NS 
Age (years)  59±9 59±13 NS 
CHD (%)  100  100  NS 
Dyslipidaemia (%)  100  100  NS 
Current smokers (%)  4.4  3.7  NS 
History of diabetes mellitus (%)  20  19  NS 
History of arterial hypertension (%)  43  42  NS 
Congestive heart failure (%)  8  7  NS 
Prior PCI/CABG (%)  35  36  NS 
Recent hospitalization for CHD (%)  7  8  NS 
Renal function K/DOQI       
 Stage 1 (%)  41  40  NS 
 Stage 2 (%)  54  53  NS 
 Stage 3 (%)  5  7  NS 
NS: not significant. 
CHD: coronary heart disease, PCI: percutaneous coronary intervention, CABG: coronary artery bypass graft, K/DOQI: Kidney Disease Outcomes and Quality Initiative. 
Table 2.  Lipid Parameters (Mean Value ± Standard Deviation) at Baseline and During the Study in the Statin Treated and Un-
treated Groups 
 
Statin Treated (n=880)  Statin Untreated (n=720)  Differences Between  
On-Study Values 
Lipid Parameter 
Baseline 
Value 
Mean On-Study Value & 
% Change vs Baseline 
Baseline 
Value 
Mean On-Study Value 
& % Change vs Baseline 
Statin vs No Statin  
P Value 
Total cholesterol (mg/dl)  258±35 164±9 -36%†  256±39 244±40 -4%  <0.0001 
LDL cholesterol (mg/dl)  181±23   99±3 -46%†  180±26 175±24 -3%  <0.0001 
VLDL cholesterol (mg/dl)  37±11   24±5 -31%†  36±9   35±10 -2%  <0.0001 
HDL cholesterol (mg/dl)  39±6   42±5 7% *  39±7   40±6 1%   0.002 
Non-HDL cholesterol (mg/dl)  219±32   125±6 - 43%†  217±29   206±31 -5%  <0.0001 
Triglycerides (mg/dl)  182±61   127±31 -30%†  179±59   173±64 -4%  <0.0001 
† P< 0.0001 vs baseline. 
* P< 0.01 vs baseline. 
LDL: low density lipoprotein, VLDL: very low density lipoprotein, HDL: high density lipoprotein 
To convert data from mg/dL to mmol/L divide total cholesterol, LDL cholesterol, VLDL cholesterol, HDL and non-HDL cholesterol values by 38.7; triglyceride values by 88.5. Statins, HDL-C, and Renal Function  The Open Cardiovascular Medicine Journal, 2007, Volume 1    11 
6. Other Factors that may have Influenced the Improve-
ment in Renal Function 
  There were no significant differences between the statin 
treated and untreated groups regarding demographic charac-
teristics, CHD risk factors at baseline (Table 1) and con-
comitant drug treatment (especially in angiotensin convert-
ing enzyme inhibitors or calcium channel blockers that might 
influence eGFR) (Table 3). The levels of glycaemic control 
and both systolic and diastolic blood pressure during the 
study were similar between the 2 groups. Both at entry and 
during the study, smokers (4.4% and 3.7%, respectively) 
were similarly distributed in the 2 treatment groups. Similar 
numbers of patients lost >10% of their body weight in the 2 
treatment groups (40 in the statin treated and 44 in the un-
treated group). Furthermore, the MDRD formula considers 
age, gender and race. Thus, it was highly unlikely that we 
had false low or false high eGFR values. Moreover, results 
were fully adjusted for 20 predictors of CHD related events 
(Tables 4 and 5). Thus, the beneficial effect on renal function 
should mainly be attributed to statin treatment. There were 
no extreme values of SCr at baseline [i.e. extremely high 
Table 3.  Medical Therapy During the Study 
 
  Statin Treated N=880  Statin Untreated N=720  P Value 
Aspirin or other antiplatelet agents (%)  87  86  NS 
Beta-blockers (%)  85  84  NS 
ACE inhibitors or ARBs (%)  54  53  NS 
Nitrates (%)  14  15  NS 
Calcium channel blockers (%)  26  27  NS 
Diuretics (%)  11  12  NS 
Statins (%)  100  0  < 0.0001 
NS: not significant. 
ACE: angiotensin converting enzyme, ARBs: Angiotensin II receptor blockers. 
 
Table 4.  Univariate Odds Ratios and 95% Confidence Intervals for eGFR Increase After the 6
th Treatment Week 
 
Univariate ORs and 95% CI for eGFR Increase 
Variables 
OR (95% CI)  P Value 
Age (years)  0.47 (0.34-0.64)  <0.0001 
Gender male  1.44 (1.07-1.93)  0.015 
CVD event during the study  0.82 (0.65-1.17)  0.2 
Use of beta-blockers during the study  0.67 (0.50-0.91)  0.02 
Use of ACE inhibitors during the study  1.27 (0.95-1.02)  0.064 
*On treatment non-HDL-C <130 mg/dL  5.60 (4.00-7.85)  <0.0001 
HDL-C with every 5% increase  3.49 (2.53-4.82)  <0.0001 
Fourteen univariate predictors of all CHD-related events all with p <0.10 (the above plus: current smoking, family history of premature CHD, history of hypertension, history of 
diabetes mellitus, prior revascularization, acute coronary syndrome, and prior myocardial infarction) were initially entered. 
*On treatment values were considered as the mean values during the entire study. 
To convert data from mg/dL to mmol/L divide non-HDL-C values by 38.7 
OR: odds ratio, CI: confidence interval, CVD: cardiovascular disease, ACE: angiotensin converting enzyme, HDL-C: high density lipoprotein cholesterol. 
 
Table 5.  Multivariate Cox Predictive Model for eGFR Increase After the 6
th Week of Treatment (Backward Stepwise Logistic Re-
gression) 
 
Multivariate Cox Predictive Model for eGFR increase 
Variables 
OR (95% CI)  P value 
Age (years)  0.79 (0.62-0.93)  0.02 
Gender male  1.32 (1.14-1.65)  0.003 
CVD event during the study  0.86 (0.64-1.37)  0.4 
Use of beta-blockers during the study  0.82 (0.61-1.19)  0.2 
Use of ACE inhibitors during the study  1.14 (0.84-1.04)  0.1 
*On treatment non-HDL-C <130 mg/dL  3.12 (1.79-5.12)  <0.0001 
HDL-C with every 5% increase  1.78 (1.19-3.34)  0.001 
Fourteen univariate predictors of all CHD-related events all with p <0.10 (the above plus: current smoking, family history of premature CHD, history of hypertension, history of 
diabetes mellitus, prior revascularization, acute coronary syndrome, and prior myocardial infarction) were initially entered. 
*On treatment values were considered as the mean values during the entire study. 
To convert data from mg/dL to mmol/L divide non-HDL-C values by 38.7 
OR: odds ratio, CI: confidence interval, CVD: cardiovascular disease, ACE: angiotensin converting enzyme, HDL-C: high density lipoprotein cholesterol. 12    The Open Cardiovascular Medicine Journal, 2007, Volume 1  Athyros et al. 
values, because patients were excluded from the study if they 
had a SCr value >1.3 mg/dl (115 μmol/l)]. The method used 
to assess SCr is reproducible and the use of mean values of a 
large number of patients together with the different effects 
on SCr in each group reduced to a minimum any regression 
to the mean effect. Moreover, there was no relation between 
HDL-C and serum uric acid levels if eGFR was taken into 
consideration. All patients in both treatment groups received 
advice on life-style changes and the body mass index (a 
rough index of compliance with life-style measures) was 
similar in both groups. 
DISCUSSION 
  We showed that renal function (represented by the 
eGFR) declines over 3 years in dyslipidaemic CHD patients 
with normal or mildly impaired renal function at baseline 
when they are not being treated with a statin. Statin treat-
ment (mainly atorvastatin) not only inhibited this deteriora-
tion but significantly increased the eGFR in these patients. It 
has been proposed that CVD and renal disease progression 
are the consequences of the same underlying disorders [18]. 
Thus, CVD risk factor reduction strategies may also be bene-
ficial in CKD [18,19]. Whether there are differences between 
statins in terms of renal benefit remains to be established 
[20].
 
  In our statin untreated patients, there was a gradual re-
duction in eGFR that became significant by the end of the 2
nd 
year of the study; renal function continued to deteriorate 
until the end of the study (a mean 3 year period). In statin 
treated patients, renal function improvement was manifest as 
early as the 6
th week of treatment; thereafter there was fur-
ther improvement that continued until the end of the study. 
The early part of renal function improvement might be at-
tributed to the pleiotropic effects of statins (e.g. anti-
inflammatory effects and improved endothelial function) 
[21]. In support of these findings, when patients with CKD 
were given statins for CVD risk reduction, they showed evi-
dence of improved renal function [22]. The improvement 
of renal function after the 6
th week of treatment might be 
related both to reduction of atherogenic lipoproteins and the 
increase of HDL-C. 
  High serum LDL-C has an adverse effect on glomerular 
mesangial cells and endothelial cells [23]. Moreover, in ani-
mal studies [24], elevated lipid content of VLDL and IDL 
played an important role in the pathogenesis of proteinuria 
and glomerulosclerosis. Clinical and experimental studies 
have demonstrated the role of lipoproteins in the decline of 
renal function with emphasis on glomerulosclerosis [25-28], 
neutrophil and macrophage infiltration [29] and upregulation 
of the cytokine interleukin (IL)-6 [30,31] or endothelial ni-
tric oxide synthase [32]. Animal studies showed that the rate 
of decline of GFR is beneficially modified after improving 
the lipoprotein profile by dietary or pharmacological ma-
nipulation, including statins [28,33]. 
  The present study addressed whether or not the statin-
induced HDL-C increase contributed to renal function im-
provement on top of LDL-C reduction and other secondary 
CVD prevention measures. HDL might improve renal func-
 
Fig. (1). Time-course of changes of HDL-C and eGFR in statin treated and in statin untreated patients. 
*P<0.0001 vs baseline. 
**P<0.0001 vs 6th treatment week. Statins, HDL-C, and Renal Function  The Open Cardiovascular Medicine Journal, 2007, Volume 1    13 
tion through several mechanisms [34]. Reverse cholesterol 
transport may contribute to the inhibition of intra-renal athe-
rosclerosis and protect against direct toxic effects of lipids 
on renal cells [35]. Inhibiting the accumulation of lipopro-
teins may also reduce LDL binding to receptors expressed by 
the mesangial cells and limit matrix production [36]. An-
other relevant mechanism might be the antioxidant effect of 
HDL [37]. However, can HDL particles protect from athero-
sclerosis or glomerulosclerosis in both low and high LDL-C 
states? Our data suggest that they can. It is also plausible that 
low LDL-C and anti-inflammatory effects of statins might 
improve HDL particle performance [39]. First, lower con-
centrations of LDL-C leave less cholesterol to be “scav-
enged” by HDL particles. Second, lowering oxidized LDL 
levels results in inhibition of growth factor receptor activa-
tion and of subsequent matrix metalloproteinase upregulation 
[37,38]. Another mechanism of action of HDL results from 
the inhibition of the production, even at low LDL-C concen-
trations, of cellular reactive oxygen species (ROS) [37]. 
  In the absence of inflammation, HDL has a complement 
of antioxidant enzymes that work to maintain an anti-
inflammatory state [39,40]. However, in the presence of sys-
temic inflammation, these antioxidant enzymes can be inac-
tivated and HDL can accumulate oxidized lipids and proteins 
that transform it to a proinflammatory particle [40]. This is 
probably the case for our statin untreated CVD patients. 
  Finally, patients on statin treatment had fewer recurrent 
CVD events during the study, thus preserving cardiac per-
formance and renal blood flow. 
STUDY LIMITATIONS 
  The study has all the restrictions of a post hoc analysis 
and there was no assessment of urine protein. In addition, we 
did not directly measure GFR; an effect of statins on creatin-
ine secretion from renal tubular cells cannot be ruled out and 
might have affected eGFR without an actual effect on renal 
function. 
CONCLUSIONS 
  There was a decline in renal function over a period of 3 
years in CHD patients not treated with statins. In contrast, 
statin treatment significantly improved renal function. There 
was a contribution of statin-induced HDL-C increase (7%) to 
this improvement over and above low non-HDL-C levels and 
other potentially beneficial therapies. This evidence supports 
the concept that improving lipid variables other than LDL-C 
may be relevant for both CHD and CKD prevention. 
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